Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing antidepressant treatment: efficacy and tolerability.

Bill Deakin1, Serdar Dursun

  • 1Neuroscience and Psychiatry Unit, University of Manchester, UK. bill.deakin@man.ac.uk

International Clinical Psychopharmacology
|October 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The functional relevance of a short assessment of formal thought disorder in psychosis.

The British journal of psychiatry : the journal of mental science·2026
Same author

Investigating the disturbance in cortical glutamate and GABA function in psychosis and its origins and consequences.

Molecular psychiatry·2025
Same author

Low-dose methotrexate as a potential treatment for schizophrenia via astrocytic and neuroimmune modulation.

Schizophrenia research·2025
Same author

Hemispheric asymmetry of [<sup>11</sup>C](<i>R)</i>PK11195 binding to translocator protein 18 kDa (TSPO) in normal brain.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2025
Same author

RSEA: A Web Server for Pathway Enrichment Analysis of Metabolic Reaction Sets.

Biotechnology and bioengineering·2025
Same author

Depressive and Negative Symptoms in the Early and Established Stages of Schizophrenia: Integrating Structural Brain Alterations, Cognitive Performance, and Plasma Interleukin 6 Levels.

Biological psychiatry global open science·2025

Dual-action antidepressants targeting serotonin and noradrenaline show potential for severe depression. These medications may offer faster onset and superior efficacy compared to SSRIs, with better tolerability than TCAs.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Dual-action antidepressants, affecting both serotonin and noradrenaline, are hypothesized to be more effective than traditional antidepressants, especially for severe depression.
  • Drugs like venlafaxine and milnacipran directly influence these pathways, while mirtazapine and nefazodone may indirectly potentiate them.

Purpose of the Study:

  • To evaluate the therapeutic benefits of dual-action antidepressants compared to selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs).
  • To assess the onset of action, efficacy, and tolerability profiles of dual-action antidepressants.

Main Methods:

  • Meta-analysis of clinical trials involving dual-action antidepressants.
  • Comparison of efficacy and tolerability data against SSRIs and TCAs.

Related Experiment Videos

Main Results:

  • Venlafaxine demonstrated a more rapid onset of action than SSRIs, with potential similar effects for milnacipran and mirtazapine.
  • Dual-action drugs, particularly venlafaxine and milnacipran, likely exhibit superior efficacy compared to SSRIs.
  • All dual-action antidepressants were better tolerated than TCAs, with milnacipran and venlafaxine showing slightly better tolerability than SSRIs.

Conclusions:

  • Dual-action antidepressants represent a promising therapeutic option for severe depression, offering potential advantages in speed of action and overall effectiveness.
  • These agents demonstrate a favorable tolerability profile, particularly when compared to TCAs, and potentially offer benefits over SSRIs.